Melatonin and the Body Clock: Timing, Evidence, and Risks
Author: Angela Bogdanova · Published: October 10, 2026 · Editorial Policy
Research cluster: Sleep, Insomnia & Circadian Psychology · Written by Artificial Sapiens
Melatonin is a hormone that communicates biological night to the body. Its rise in dim light is one of the clearest signals of the circadian system, and carefully timed supplemental melatonin can sometimes help move sleep timing or ease jet lag. The clinically important question is not simply whether melatonin makes someone sleepy. It is whether a particular person has a circadian timing problem, what direction their internal clock needs to move, and whether the planned timing, formulation, and medical context make the intervention appropriate.
The same supplement can produce different outcomes at different biological times. It may help someone whose internal night begins much later than their required schedule; it may provide little meaningful benefit for persistent insomnia driven by conditioned wakefulness; and incorrectly timed use can work against the intended adjustment. The American Academy of Sleep Medicine clinical guideline supports strategically timed melatonin for selected circadian disorders, with conditional recommendations and important limits. The National Center for Complementary and Integrative Health (NCCIH) summarizes a similarly uneven evidence base across indications.
What is melatonin?
Melatonin is produced primarily by the pineal gland under control of the brain's central circadian pacemaker, the suprachiasmatic nucleus (SCN) in the hypothalamus. Environmental light detected by the eyes informs that pacemaker about the external day–night cycle. In ordinary circumstances, endogenous melatonin secretion rises during the biological evening, remains elevated across much of the biological night, and falls toward biological morning. Nighttime light can suppress the signal, especially when exposure is sufficient and appropriately timed.
Melatonin is therefore useful as a signal of circadian phase. Its occurrence tells the body that internal night has arrived; it does not independently determine whether a person has accumulated enough homeostatic sleep pressure, is emotionally calm, has an unobstructed airway, or is able to sleep. Sleep emerges through the interaction of circadian timing, time awake, behavioral patterns, psychological arousal, health, and environment. This explains why taking a hormone associated with nighttime does not solve every cause of sleeplessness. The NIH NCCIH overview describes the relationship between darkness, melatonin, and circadian timing.
Natural melatonin and a purchased melatonin supplement are related but different exposures. Endogenous secretion occurs in a biological rhythm; an oral supplement introduces an externally timed dose, with exposure affected by formulation, absorption, metabolism, and product accuracy. Some preparations release the hormone quickly, whereas prolonged-release products produce a different concentration–time profile. Results from one formulation, population, or indication cannot automatically be transferred to another.
The body clock: timing, phase, and sleep pressure
The human circadian system organizes approximately 24-hour changes in sleep propensity, alertness, temperature, hormonal secretion, and other physiological processes. Its phase describes where a person is in their internal day. Chronotype describes a person's tendency toward earlier or later activity and sleep preference, while circadian misalignment describes a mismatch between the internal clock and an imposed or desired schedule. A late chronotype by itself is a normal variation; a circadian rhythm sleep-wake disorder requires a clinical pattern of disruption and significant functional consequences.
Two people can both go to bed at 11 p.m. while inhabiting very different biological times. For one person, 11 p.m. is well into biological night. For another, especially a person with a markedly delayed circadian phase, that clock time may still fall in their biological evening. Their responses to light and melatonin depend in part on this internal phase. A fixed clock time printed on a supplement label cannot account for those differences.
Sleep pressure accumulates during wakefulness and dissipates during sleep. Melatonin's clock signal interacts with sleep pressure, but does not substitute for it. Someone can feel drowsy after melatonin without achieving restorative sleep, and someone may fall asleep naturally despite low measured melatonin under certain conditions. Neither experience alone establishes a hormone deficiency.
How melatonin shifts the circadian clock
Supplemental melatonin has at least two clinically relevant effects: a direct sleep-promoting or soporific effect in some circumstances, and a time-dependent phase-shifting effect on circadian rhythms. The distinction matters because these effects are not identical. Feeling sleepy after swallowing a tablet provides little information about whether the underlying clock moved earlier or later.
A phase response curve describes how an intervention's effect changes with the circadian time at which it is delivered. Controlled human experiments show that melatonin given during the biological afternoon or evening tends to advance circadian phase, moving internal timing earlier, while administration in the biological morning can delay it. The magnitude varies with biological phase, individual factors, and study conditions. These principles were demonstrated in Burgess and colleagues' experimental phase-response research and underpin the AASM clinical guideline.
Light has its own phase response curve, broadly opposite to that of melatonin: light in the appropriate biological morning generally advances the clock, while light at certain biological evening or night times can delay it. Bright light can also suppress naturally secreted melatonin. These interacting effects are why melatonin should be considered within a whole timing plan that includes light, darkness, wake time, and daily commitments, rather than as an isolated nightly tablet.
What does an advance or delay actually mean?
A phase advance means that internal circadian events, potentially including the onset of biological night, move earlier relative to the clock on the wall. A phase delay moves them later. These shifts can matter when someone naturally falls asleep at 3 a.m. but needs to sleep earlier, when an eastward flight demands an earlier destination schedule, or when treatment for another circadian condition requires a different directional adjustment.
The desired shift is based on a clinical assessment. A person with an advanced sleep-wake phase should not assume that the same evening melatonin timing helpful for some delayed-phase patients will correct their situation. And a person whose problem is frequent awakenings despite correctly timed sleep may require assessment for insomnia, sleep apnea, movement disorders, pain, medication effects, or another cause rather than deliberate phase shifting.
Dim light melatonin onset (DLMO): the biological marker
Dim light melatonin onset, abbreviated DLMO, is the point at which melatonin begins to rise above a defined threshold when samples are collected under controlled dim-light conditions. Researchers and specialized clinics may estimate it from serial saliva or blood samples. DLMO is a marker of the phase of the central clock, and its relationship to attempted bedtime can clarify whether a person's sleep schedule is aligned with their circadian system.
DLMO is more precise for this purpose than a wrist wearable's sleep score or a person's estimate of when they became drowsy. It does, however, depend on valid collection procedures, assay methods, recent light exposure, and interpretation. Many patients are assessed through a clinical history and a sleep diary, often assisted by actigraphy, without laboratory phase testing. The AASM circadian guideline discusses the role of phase markers in selected cases.
DLMO should not become a requirement that every reader attempts to measure or optimize at home. It is useful when a specialist needs to resolve diagnostic uncertainty or devise timing-sensitive treatment. Consumer trackers do not directly measure melatonin secretion and cannot establish a circadian diagnosis by themselves.
When should melatonin be taken for the body clock?
The useful answer depends on the goal and biological phase. For a person with a confirmed delayed sleep-wake phase disorder, treatment may aim to move the internal clock earlier. For jet lag, the target is adjustment to destination time. For other circadian disorders, the appropriate intervention may involve different timing or a different primary treatment. Taking melatonin a fixed number of minutes before every bedtime is a sleep-aid convention, not a universal circadian treatment rule.
Experimental phase response curves suggest that the strongest advances may occur when melatonin is administered before a person's natural rise in the hormone, which can be several hours before habitual sleep. Other treatment trials deliberately administered melatonin closer to a desired bedtime, targeting sleep initiation along with scheduled behavior. Both approaches have been studied; their goals and populations differ. Burgess et al. investigated phase shifts, while Sletten et al. studied patients with clinically characterized delayed sleep-wake phase disorder using melatonin combined with behavioral scheduling.
This is why a single chart labeled “best time to take melatonin” can mislead. It may silently assume the person's circadian phase, the intended direction of adjustment, the destination time zone, the formulation, and a diagnosis that has not been established. The practical approach is to identify the reason for use before discussing timing with a qualified clinician or pharmacist. People with complex medical or psychiatric conditions, young children, pregnancy, interacting medications, or significant daytime impairment particularly need individualized review.
Why timing can matter more than taking a larger dose
A larger dose does not necessarily create a larger or better-directed phase shift. Supplemental melatonin may extend exposure into biological periods in which the intended phase effect is smaller or different, and larger exposure can increase next-day drowsiness for some people. The AASM review notes that optimal dosing remains uncertain for many circadian conditions and emphasizes timing rather than assuming a simple dose–response relationship. Supplement bioavailability and measured content vary substantially, adding further uncertainty. The AASM guideline and Goldstein and Burgess's clinical commentary address this issue.
Numbers used in clinical trials are evidence about the protocols studied, not an individualized prescription. A product's milligram label also does not establish the amount actually delivered. Anyone already prescribed a melatonin-related medicine or other medication should discuss changes with their treating professional rather than extrapolating from a research paper.
Evidence for delayed sleep-wake phase disorder
Delayed sleep-wake phase disorder (DSWPD) involves a persistently later sleep–wake schedule than required or desired, difficulty sleeping and waking at conventional obligations, and clinically meaningful consequences. When allowed their preferred late schedule, some affected people sleep a normal duration and with relatively normal continuity. DSWPD therefore differs from a preference for staying up late and from insomnia that persists even when sleep timing is unrestricted.
The 2015 AASM guideline conditionally suggests strategically timed melatonin for adults with DSWPD, with or without depression. It also includes conditional pediatric recommendations for selected DSWPD groups. The guideline's evidence was limited and heterogeneous; its positive recommendation should be interpreted in the context of a diagnosed disorder and clinician-guided timing.
A particularly informative 2018 randomized, placebo-controlled trial by Sletten and colleagues enrolled clinically diagnosed patients whose endogenous melatonin rhythm was delayed relative to desired bedtime. Participants receiving immediate-release melatonin alongside a prescribed behavioral sleep–wake schedule fell asleep approximately 34 minutes earlier than those receiving placebo with the same schedule, on the study's primary outcome. This establishes a clinically relevant benefit under that protocol; it does not mean every late sleeper will respond or that a single supplement dose permanently resets the clock.
Behavioral scheduling and morning light exposure may matter alongside pharmacological timing. A stable schedule helps maintain any gained alignment. Evening light, variable wake times, and competing social demands can undermine a desired shift. The relevant clinical goal is sustainable sleep and daytime functioning, including adequate sleep duration, rather than shifting the clock simply to achieve an arbitrary early bedtime.
Evidence for jet lag
Jet lag is a temporary mismatch between the circadian system and local time after travel across time zones. It can involve sleep difficulty, daytime fatigue, impaired concentration, altered appetite, and gastrointestinal symptoms. The direction of travel, number of time zones, travel schedule, light exposure, and length of stay all affect adaptation.
The Cochrane review by Herxheimer and Petrie found that melatonin reduced jet-lag symptoms in several randomized trials, especially in flights spanning multiple time zones when taken near the target bedtime at the destination. The NCCIH guidance for travelers also recognizes potential benefit while emphasizing correct timing and safety. The evidence base includes older trials with differences in study designs, doses, directions of travel, and outcomes, so certainty about a best protocol for every itinerary is limited.
Morning and evening in the destination time zone are relevant, but the person's biological clock may still be operating close to home time. Poorly timed melatonin can produce daytime sleepiness or hinder adjustment, and taking it early in the destination day is specifically cautioned against by NCCIH. Timed daylight, appropriate opportunities for darkness and sleep, and realistic expectations about adaptation remain important. A flight-specific plan should take account of direction, destination, medical circumstances, and whether the traveler must drive or perform safety-sensitive tasks shortly after arrival.
Melatonin for non-24-hour sleep-wake rhythm disorder
Non-24-hour sleep-wake rhythm disorder involves a circadian sleep–wake phase that drifts progressively across successive days when the internal clock does not reliably synchronize to the environmental 24-hour cycle. It occurs particularly among some totally blind people who receive insufficient light information through the eyes, although diagnostic considerations differ in sighted patients.
The AASM guideline conditionally supports strategically timed melatonin for non-24-hour sleep-wake rhythm disorder in blind adults. The recommendation draws on relatively small studies, and the appropriate aim is entrainment or stabilization of the circadian rhythm, not merely immediate sedation. Diagnosis commonly requires longitudinal sleep–wake patterns rather than a single night of poor sleep.
Longitudinal monitoring, access to specialist assessment, and sustained treatment planning matter. The treatment of non-24-hour rhythms is distinct from treating a delayed phase that remains roughly fixed, from ordinary irregular schedules, and from jet lag that resolves after travel. It also differs from non-24-hour rhythms associated with neurological or developmental conditions, for which evidence must be interpreted separately.
What about advanced phase, irregular rhythms, and shift work?
Advanced sleep-wake phase disorder involves an internal sleep period that is earlier than desired or required. It is not simply waking early one morning. Treatment logic differs from DSWPD, and the 2015 AASM guideline did not make a positive melatonin recommendation for adult advanced-phase disorder because of insufficient evidence. The guideline instead conditionally supported evening light therapy in selected adults.
Irregular sleep-wake rhythm disorder involves an unusually fragmented, poorly organized sleep pattern over the 24-hour day, in some cases associated with neurological disease and residential care. The AASM guideline recommended against melatonin use for older adults with dementia-related irregular sleep-wake rhythm disorder. This is a specific safety- and population-sensitive judgment, not a blanket claim about every individual older adult. The AASM guideline provides its evidence assessment.
Shift work sleep disorder involves insomnia, excessive sleepiness, or both in relation to work schedules that repeatedly overlap habitual sleeping hours. The evidence on melatonin for shift workers is mixed and is weaker than a simplistic claim that melatonin solves night-shift adaptation. A shift worker's goals may also conflict: the person may want sleep during daytime after work while maintaining a different schedule on days off. The NCCIH melatonin summary describes inconclusive shift-work studies. Occupational safety and assessment of excessive sleepiness should be prioritized over an improvised supplement plan.
Can melatonin treat insomnia?
Difficulty falling asleep is a symptom that can arise from several conditions. Chronic insomnia disorder involves persistent difficulty initiating or maintaining sleep, or waking too early, despite adequate opportunity and circumstances for sleep, together with associated daytime impairment and a characteristic duration and frequency pattern. The clinician evaluates possible contributing conditions, including circadian misalignment, pain, sleep apnea, restless legs symptoms, psychiatric conditions, and medications.
For chronic insomnia in adults, the evidence-supported first-line treatment is multicomponent cognitive behavioral therapy for insomnia (CBT-I). The 2021 AASM behavioral-treatment guideline strongly recommends CBT-I and advises against sleep hygiene as the only treatment. The American College of Physicians guideline likewise recommends CBT-I as the initial treatment. A related 2026 AASM combination-treatment guideline addresses when insomnia medication might be combined with CBT-I; it should not be read as blanket support for OTC melatonin.
The AASM pharmacologic insomnia guideline suggested against melatonin for sleep-onset or sleep-maintenance insomnia in adults, on the evidence available for that indication. This recommendation is consistent with recognizing melatonin's usefulness in selected circadian disorders. Treating a late internal clock and treating chronic insomnia are different clinical tasks.
People who say “melatonin didn't work” may have taken it at an unhelpful phase, may have a sleep problem unrelated to circadian timing, may have used a product with unexpected contents, or may have had a condition requiring different treatment. A disappointing experience alone does not identify which explanation applies. Similarly, a night of improved sleep does not confirm a diagnosis of low melatonin.
Melatonin in children and adolescents
Young people can have late sleep timing because adolescence is associated with changes in circadian phase and social schedules. Children can also have behavioral sleep problems, neurodevelopmental conditions, psychiatric conditions, medical sleep disorders, or inconsistent sleep opportunities. Each situation asks a different clinical question. A supplement that shortens time to sleep on some nights does not establish that ongoing treatment is necessary or appropriate.
The American Academy of Sleep Medicine's health advisory advises parents and caregivers to discuss melatonin with a pediatric health care professional before starting it. It emphasizes the need to consider schedules and behaviors, to individualize timing and dose if use is appropriate, and to store melatonin like medication. Evidence for specific pediatric populations should not be generalized to all children who resist bedtime.
Questions about long-term growth, puberty, chronic use, formulation differences, and interactions require appropriate clinical follow-up because long-term safety information remains incomplete. The NCCIH evidence summary also highlights this uncertainty. For an adolescent with major difficulty waking for school, a specialist may investigate a circadian disorder rather than simply increasing bedtime supplementation.
Accidental pediatric ingestion is a serious household safety issue. A 2024 CDC analysis estimated approximately 11,000 emergency-department visits among children age five or younger in the United States during 2019–2022 for unsupervised melatonin ingestion; flavored gummies were implicated in many cases. Keep all products locked or otherwise inaccessible, and seek local poison-control or emergency advice promptly if a child consumes an unknown or potentially excessive amount.
Safety: side effects, interactions, and people who need additional caution
Commonly reported short-term side effects include sleepiness, headache, dizziness, and nausea. Unwanted drowsiness can impair driving, work, and decision-making, especially when melatonin is taken at a biologically inappropriate time or when combined with other sedating substances. Individual responses are variable, and short-term tolerability does not establish long-term safety. The NIH NCCIH overview summarizes the available safety research.
People taking anticoagulants or other medicines affecting bleeding, those with epilepsy or seizure disorders, and people with significant medical conditions should speak with a clinician before use. Medication interactions and comorbidities may change the balance of benefit and risk. Patients who are pregnant or breastfeeding should obtain medical advice because reliable safety information in these populations is limited. Older adults may experience more prolonged effects or daytime drowsiness, and people with dementia require careful evaluation in light of disorder-specific guideline recommendations.
Patients with bipolar disorder or vulnerability to mania should be particularly cautious about any self-directed attempt to manipulate sleep–wake timing, including light or melatonin schedules that disturb sleep. Maintaining stable sleep and coordinating with the treating clinician matter when circadian treatment intersects with mood-episode risk. For a fuller discussion of that condition-specific question, see Bipolar Disorder and Sleep.
It is important to distinguish an adverse event temporally following melatonin from a proven causal effect. Large observational associations involving long-term supplement users can be strongly confounded by underlying insomnia, illness, age, other medications, and reasons for taking the product. Such associations warrant investigation; they cannot alone establish that melatonin caused the observed health outcome. Similarly, an absence of frequent serious side effects in short trials does not establish that unrestricted long-term use is safe.
Supplements, product quality, and U.S. regulation
In the United States, melatonin is generally sold as a dietary supplement. Dietary supplements are regulated under a different framework from FDA-approved prescription or over-the-counter medications, and marketing availability should not be mistaken for demonstrated effectiveness for each clinical indication. Other countries regulate melatonin differently; recommendations and product standards may therefore vary across borders. The NCCIH explanation describes this distinction.
Product-content variability is a tangible risk. In a 2017 laboratory analysis by Erland and Saxena, measured melatonin content differed considerably from labels across tested commercial products, and serotonin was detected in some samples. A later 2023 U.S. analysis of melatonin gummies likewise found substantial label discrepancies among sampled products, including products containing cannabidiol. These are studies of purchased samples, not prevalence estimates for all products at all times, but they demonstrate why assuming exact dosing from the label can be unsafe.
Independent quality certification may improve confidence about manufacturing and labeled content, but it cannot determine whether melatonin is clinically appropriate for the user or correctly timed for the desired phase shift. Products marketed as “natural” can still have pharmacological effects and interactions. More milligrams, multiple simultaneous sleep supplements, or elaborate proprietary blends are not evidence of better circadian treatment.
Immediate-release versus prolonged-release melatonin
Immediate-release preparations produce a comparatively shorter exposure intended to make melatonin available soon after ingestion. Prolonged-release preparations distribute exposure over a longer interval. Formulation can affect perceived sleepiness, residual effects, and the relationship between administration time and circadian phase. Studies that use immediate-release melatonin should not be casually treated as evidence for an equivalent prolonged-release regimen.
Some prescription formulations or melatonin-receptor agonists are regulated as medications and have indication-specific evidence, dosing, adverse effects, and prescribing requirements that differ from U.S. supplements. Melatonin itself and drugs that act on melatonin receptors are related pharmacologically but should not be treated as interchangeable. A clinician should review the specific product and intended condition; changing between formulations without review can change timing and exposure.
Melatonin and light: why the environment changes the result
Morning light and evening darkness provide powerful timing information to the circadian system. Exposure to bright or blue-enriched light during biological night can suppress endogenous melatonin and influence the clock, while exposure during an appropriate biological morning can help move timing earlier. The impact depends on intensity, spectrum, duration, prior light history, and biological phase. The AASM circadian guideline reviews light's phase-shifting principles.
For a person attempting an earlier schedule, persistent bright late-evening light may counteract the intended direction. A regular wake schedule, appropriately timed daylight, and a comfortable dark sleep environment may support the broader plan. Yet “get morning light” also requires context: a shift worker returning home from an overnight shift or a person whose biological night extends into conventional morning may need different timing to achieve a different objective.
Evening phone use can influence sleep through multiple pathways: light, psychological stimulation, displacement of sleep opportunity, and repeated engagement. The independent English Hub article Screen Time and Sleep covers this issue without reducing sleep disruption to melatonin suppression alone. Light therapy and melatonin timing should be assessed together where an actual circadian disorder is diagnosed.
Why caffeine, alcohol, and routines still matter
Caffeine can temporarily reduce perceived sleepiness while interfering with sleep pressure and sometimes sleep continuity. Alcohol may initially feel sedating while disturbing later sleep. Variable work hours, naps, inconsistent waking, and stress can further complicate the picture. None of these necessarily indicates a melatonin deficiency. Coffee and Sleep provides the distinct evidence base for caffeine timing and individual sensitivity.
Regular meals, physical activity, light exposure, and social routines can provide additional daily time cues, though their effects vary and are usually less direct than light for human circadian alignment. A plausible mechanism is not the same as proof that a specific ritual will entrain a diagnosed disorder. A clinical plan needs to prioritize which cues are relevant to the person's measured or inferred circadian problem.
How clinicians evaluate a suspected circadian problem
A thoughtful assessment starts with the pattern across days and weeks: when the person naturally becomes sleepy, when they fall asleep and awaken, whether sleep improves on unrestricted days, how the schedule changes on weekends or vacations, whether there is rotating work or recent time-zone travel, and how daily functioning is affected. Sleep diaries and sometimes actigraphy can help reveal regular delay, advance, drift, or fragmentation. Circadian phase testing may be valuable in selected cases.
Clinicians consider other causes of apparent sleep timing trouble, including insufficient sleep opportunity, chronic insomnia, obstructive sleep apnea, restless legs syndrome, depression or anxiety, medication effects, substance use, and neurological conditions. Significant unintentional sleep episodes, unsafe drowsy driving, loud snoring with witnessed pauses in breathing, injuries during unusual sleep behaviors, or rapidly deteriorating functioning call for a more complete assessment.
Screening questionnaires, sleep trackers, and informal “night owl” labels can support conversations but do not establish an ICSD-3-TR clinical diagnosis. A normal chronotype, a temporarily delayed schedule after holidays, and delayed sleep-wake phase disorder can look superficially similar. The distinction is made through persistence, context, functional impact, and appropriate professional evaluation.
A practical decision framework
Before considering supplemental melatonin, identify the specific problem in plain language. Is the person sleeping well on a consistently late schedule but unable to wake for obligations? Are they adapting to travel across time zones? Do they sleep poorly at nearly every schedule? Do they work nights, have repeated awakenings, or experience dangerous daytime sleepiness? These scenarios may require fundamentally different interventions.
Next, establish whether there is enough sleep opportunity and whether the schedule is stable enough to interpret. Review exposure to light and darkness, current medications, other supplements, alcohol, caffeine, medical problems, pregnancy, and any history of seizures or mood episodes. A clinician may then determine whether timing-sensitive melatonin is appropriate, what treatment outcome would demonstrate benefit, and when to reassess. No universally safe phase-shifting hour or milligram amount follows from the word “melatonin” alone.
If a medically supervised trial is undertaken, useful outcomes can include consistency of sleep timing, ability to fall asleep at the intended phase, sufficient sleep duration, daytime alertness, functioning, adverse effects, and whether benefits remain after the intervention ends. A sleep diary may provide more interpretable information than chasing small changes in a consumer sleep score. If the treatment seems ineffective or causes next-day impairment, the diagnosis, phase estimate, formulation, adherence, and alternative conditions warrant review before any change.
For people with chronic insomnia, referral for CBT-I is often a better match than continually trying bedtime supplements. For people with suspected obstructive sleep apnea, excessive daytime sleepiness, or serious parasomnia behavior, the priorities are disorder-specific evaluation and safety, irrespective of whether they also have a late schedule.
Questions people frequently ask
Is melatonin a sleeping pill?
Melatonin can have a sleep-promoting effect, but its circadian signaling and phase-shifting functions make it different from conventional sedative-hypnotic medications. It does not reliably treat every reason someone is awake at night. The appropriate indication matters more than the label “natural sleep aid.”
What time should I take melatonin to reset my circadian rhythm?
There is no clock hour that suits everyone. The intended direction of phase shift, the person's biological time, formulation, clinical diagnosis, and light schedule matter. Published studies evaluate specific protocols rather than establishing a universal instruction. Seeking individualized timing guidance is especially important for recurrent symptoms or medical risk factors.
Can taking melatonin at the wrong time make sleep timing worse?
Yes, in principle. The direction of phase shifting changes with biological time, and unwanted daytime drowsiness can occur. This is why morning, afternoon, and evening dosing are not interchangeable. The phase-response evidence is described by Burgess and colleagues.
Does more melatonin work better?
The evidence does not establish that increasing a dose consistently improves circadian shifting or insomnia. Higher exposure can add adverse effects, and product contents vary. A dose used in one trial should not be generalized to a different person, formulation, or condition.
How long does melatonin take to change the body clock?
Circadian change is not equivalent to how quickly sleepiness begins after swallowing a supplement. Phase adjustment may require repeated appropriately timed interventions across days or weeks, depending on the condition and accompanying light and schedule. The effect should be assessed through relevant sleep–wake outcomes, not a promised one-night reset.
Does melatonin help night owls?
An evening preference is not a diagnosis. Some people with clinically significant delayed sleep-wake phase disorder may benefit from strategically timed melatonin and a structured schedule, but people who prefer late hours and function well may not need treatment. See the AASM guideline for the disorder-specific evidence.
Is it effective for jet lag?
Melatonin may reduce jet-lag symptoms for some travelers, especially after crossing multiple time zones, but benefits and appropriate timing depend on the itinerary. Destination bedtime, biological time, and safe functioning after travel should all inform a plan. NCCIH traveler guidance offers an authoritative overview.
Can melatonin cure chronic insomnia?
No general evidence establishes melatonin as a cure for chronic insomnia disorder. Multicomponent CBT-I remains the recommended initial treatment in adults, and evaluation may uncover conditions that require separate care. AASM's behavioral treatment guideline explains the recommendation.
Is daily or long-term melatonin safe?
Short-term studies suggest acceptable tolerability for many people, while long-term safety remains incompletely characterized, especially in children and special populations. Long-term use should be reviewed in light of the indication, possible interactions, product quality, adverse effects, and whether the intervention is still needed. NCCIH describes these evidence limits.
Does melatonin stop my body from making its own?
Strong evidence that typical clinical use permanently suppresses the body's ability to produce melatonin is lacking. At the same time, research does not resolve every question about prolonged external exposure in every population. The main established issues in routine decision-making remain accurate indication, timing, product quality, adverse effects, and unknown long-term outcomes.
Can I rely on a sleep tracker to time melatonin?
A consumer tracker may estimate periods of sleep and activity but does not directly measure DLMO or establish the phase of the central clock. Its readings can assist a diary, but they are not a substitute for professional diagnosis or specialist circadian phase testing when that is needed.
When should I seek medical help rather than experiment?
Seek evaluation for persistent sleep–wake impairment, suspected sleep apnea, dangerous sleepiness while driving or working, symptoms suggestive of a neurological sleep disorder, significant distress despite adequate sleep opportunity, or a young child's repeated sleep difficulty. Contact a clinician promptly for a serious reaction or medication interaction. For possible poisoning or excessive ingestion, seek immediate poison-control or emergency guidance.
What the evidence supports
The most defensible conclusion is conditional and specific. Melatonin is an established biological night signal. Controlled physiology research demonstrates that externally administered melatonin can shift human circadian rhythms in a timing-dependent direction. Clinical studies and guidelines support appropriately timed use for selected circadian disorders and jet lag, with uncertainty about optimal regimens and long-term use. Chronic insomnia, poorly defined “bad sleep,” and every preference for late hours do not become melatonin-deficiency conditions.
A useful clinical decision integrates the person's actual sleep timing, diagnosis, lifestyle obligations, concurrent light exposure, medications, vulnerabilities, product reliability, and functional outcome. Circadian medicine is about alignment over time. Its accuracy comes from recognizing biological phase and treating the specific problem, not from increasing supplement intensity.
Related Articles
Screen Time and Sleep: How Evening Device Use Affects Bedtime and Rest — evening light, engagement, and behavior.
Bipolar Disorder and Sleep: Mood Episodes, Circadian Rhythms, and Prevention — sleep stability and mood-episode safety.
Anxiety and Sleep: Insomnia, Hyperarousal, and the Anxiety-Sleep Cycle — a differential pathway when worry and arousal perpetuate insomnia.
Coffee and Sleep: How Caffeine Timing, Dose, and Sensitivity Affect Rest — an independent explanation of caffeine-related sleep disruption.
References
American Academy of Sleep Medicine. (2022). Health advisory: Melatonin use in children and adolescents.
Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: An update for 2015. Journal of Clinical Sleep Medicine, 11(10), 1199–1236. https://doi.org/10.5664/jcsm.5100.
Burgess, H. J., Revell, V. L., Molina, T. A., & Eastman, C. I. (2010). Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. Journal of Clinical Endocrinology & Metabolism, 95(7), 3325–3331. https://doi.org/10.1210/jc.2009-2590.
Centers for Disease Control and Prevention. (2024). Notes from the field: Emergency department visits for unsupervised pediatric melatonin ingestion—United States, 2019–2022. MMWR, 73, 215–217. https://www.cdc.gov/mmwr/volumes/73/wr/mm7309a5.htm.
Cohen, P. A., Avula, B., Wang, Y.-H., Katragunta, K., & Khan, I. (2023). Quantity of melatonin and CBD in melatonin gummies sold in the US. JAMA, 329(16), 1401–1402. https://doi.org/10.1001/jama.2023.2296.
Edinger, J. D., et al. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 17(2), 255–262. https://doi.org/10.5664/jcsm.8986.
Erland, L. A. E., & Saxena, P. K. (2017). Melatonin natural health products and supplements: Presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine, 13(2), 275–281. https://doi.org/10.5664/jcsm.6462.
Goldstein, C. A., & Burgess, H. J. (2020). Hit or miss: The use of melatonin supplements. Journal of Clinical Sleep Medicine, 16(suppl 1), 29S–30S. https://pmc.ncbi.nlm.nih.gov/articles/PMC7792888/.
Herxheimer, A., & Petrie, K. J. (2002). Melatonin for preventing and treating jet lag. Cochrane Database of Systematic Reviews, CD001520. https://doi.org/10.1002/14651858.CD001520.
National Center for Complementary and Integrative Health. (n.d.). Complementary health approaches for travelers.
National Center for Complementary and Integrative Health. (n.d.). Melatonin: What you need to know.
Qaseem, A., et al. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165, 125–133. https://pubmed.ncbi.nlm.nih.gov/27136449/.
Sateia, M. J., et al. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. Journal of Clinical Sleep Medicine, 13(2), 307–349. https://pubmed.ncbi.nlm.nih.gov/27998379/.
Sletten, T. L., et al. (2018). Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial. PLOS Medicine, 15(6), e1002587. https://doi.org/10.1371/journal.pmed.1002587.